

THRU ONLINE FILING

June 16, 2025

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Dr. Nagaji Ambabhai Vekariya has joined the Company as President – CRD.

Details of the appointee, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, are as under:

Name : Dr. Nagaji Ambabhai Vekariya – President – CRD		
1.	Reason for Change	Appointed as President – CRD
2.	Date of appointment & term of appointment	16 th June, 2025
3.	Brief Profile (in case of appointment)	Dr. Vekariya has completed his PhD in Organic Chemistry from Saurashtra University. Dr. Vekariya brings with him a professional experience of over 23 years. He started his career with Alembic Pharmaceuticals Ltd in the year 2001 and thereafter worked with companies like Glenmark Pharmaceuticals, Lupin Ltd, Aurobindo Pharma Ltd, Macleods Pharmaceuticals Ltd. & Neuland Laboratories Ltd. Prior to joining us, he was associated with Sekhmet Pharmaventures Pvt Ltd as Head - API & Formulations R&D. Throughout his career, he has successfully led complex research initiatives, enabled global regulatory filings and played a pivotal role in advancing long term innovation strategies.
4.	Disclosure of relationships between directors	He is not related to any Director or Key Managerial Personnel of the Company.

Kindly take this information on your records.

Thanking you

Yours faithfully

For Ipca Laboratories Limited

Harish Kamath
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.
www.ipca.com